Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial
"With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need." According to Eli Lilly, adults in the Phase 3 trials all lost weight with orforglipron and on the highest dose of 36 mg of orforglipron, the trial participants lost about 27 pounds over the course of 72 weeks or about 12% of their body weight, which is meaningful but not quite as high as some injectables
Key takeaways The numbers: approximately 13.6% average weight loss with the Wegovy pill and 14.9% with the 2.4mg injection
Hims is the consumer-health brand aimed at men that advertises branded GLP-1s along with a compulsory membership fee
Do you qualify for the DOCS Medical Obesity Management program
For two-group comparisons, a two-tailed Students t-test was used for normally distributed data, and the MannWhitney U test was applied otherwise